Jefferies Group Gives Buy Rating to Nektar Therapeutics (NKTR)

By admin | 6 years ago

Nektar Therapeutics (NASDAQ: NKTR)‘s stock had its “buy” rating reaffirmed by Jefferies Group (NYSE: JEF) in a research note issued on Wednesday.

Separately, analysts at Roth Capital initiated coverage on shares of Nektar Therapeutics in a research note to investors on Thursday, May 24th. They set a “buy” rating on the stock.

Nektar Therapeutics opened at 6.82 on Wednesday. Nektar Therapeutics has a 52-week low of $4.07 and a 52-week high of $8.50. The company’s market cap is $781.6 million.

Nektar Therapeutics last posted its quarterly earnings results on Wednesday, May 2nd. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.33) by $0.03. The company’s quarterly revenue was up 58.4% on a year-over-year basis. Analysts expect that Nektar Therapeutics will post $-0.32 EPS next quarter.

Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients.

About the author